The gene NEB encodes for the skeletal muscle protein nebulin. Mutations in NEB cause the disease nemaline myopathy, which is one of the more common inherited myopathies. Patients with this muscle disorder have muscle weakness in multiple different parts of their body and can also experience difficulties with feeding or breathing. Currently, there is no cure for nemaline myopathy and treatment options are limited. Therefore, there is a need to better understand this disease and design new therapeutics that can improve patient quality of life. In a recent Nature Communications article, a team of researchers from the University of Arizona working to provide new insights into the pathogenesis of this skeletal muscle disorder report a new mouse model of nemaline myopathy that exhibits similar symptoms to those identified in human patients. An important part of this work utilized x-ray diffraction data collected at the U.S. Department of Energy’s (DOE’s) Advanced Photon Source (APS). The diffraction data provide new insights into how mutations of NEB alter the molecular structure of skeletal muscles. The findings from the study are highly impactful because they significantly increase our understanding of how mutations in the gene NEB cause nemaline myopathy. Importantly, the new mouse model of this disease can be used to test future therapeutics. Future studies are warranted to determine if interventions can relieve disease symptoms in these mice. If successful, such therapeutics could be used for improving the quality of life in human patients.

Nemaline myopathy is a rare muscle disease that can be caused by mutations in the gene NEB. Over 240 different disease-causing mutations in NEB have been identified in conjunction with nemaline myopathy, with the majority of patients having two different mutations in the gene NEB. Patients experience symptoms ranging from muscle weakness in the arms, legs, face, and neck to difficulties with feeding or breathing. Despite these serious symptoms, there is currently no cure and the available treatment options are limited.

From a functional standpoint, NEB encodes for the protein Nebulin, which is found in the sarcomere of skeletal muscle. Unlike cardiac and smooth muscle which undergo involuntary muscle contractions, skeletal muscles are under voluntary control and are responsible for carrying out bodily movements. For example, someone performing bicep curls in the gym is actively controlling and exercising their biceps using skeletal muscles.

To gain more insight into the molecular structures and mechanisms underlying the disease nemaline myopathy, the researchers from the University of Arizona developed a novel animal model to study this skeletal muscle disorder. To do this, they created genetically modified mice harboring two different mutations in NEB. One of these mutations is a missense mutation (resulting in a single amino acid change) and the other mutation is a deletion mutation (meaning that a portion of the gene has been removed). The result of these two mutations is a class of genetically modified mice that exhibit similar symptoms as humans with nemaline myopathy. These genetically modified mice also weighed less and have a shorter tibia bone compared to genetically normal controls.

Using the new mouse model, the team examined how these two mutations impacted the structure of the muscle on a molecular level. A key part of this work was performed in collaboration with Illinois Institute of Technology scientists at the Biophysics Collaborative Access Team (Bio-CAT) 18-ID-D x-ray beamline at the APS (the APS is an Office of Science user facility at Argonne National Laboratory). X-ray diffraction patterns collected at beamline 18-ID were used to identify molecular structures altered in the mice (Fig. 1). The research team found that the sarcomeres in the new strain of genetically modified mice were disorganized. One prominent finding was that actin filaments―which play an important role in muscle contraction―were twisted and have a larger radius when compared to the control.  ― Stephen Taylor

See: Johan Lindqvist¹, Weikang Ma², Frank Li¹, Yaeren Hernandez¹, Justin Kolb¹, Balazs Kiss¹, Paola Tonino¹, Robbert van der Pijl¹, Esmat Karimi¹, Henry Gong2, Josh Strom¹, Zaynab Hourani¹, John E. Smith III¹, Coen Ottenheijm¹, Thomas Irving², and Henk Granzier¹*, “Triggering typical nemaline myopathy with compound heterozygous nebulin mutations reveals myofilament structural changes as pathomechanism,” Nat. Commun. 11, 2699 (2020). DOI: 10.1038/s41467-020-16526-9

Author affiliations: ¹University of Arizona, ²Illinois Institute of Technology

Correspondence: *granzier@email.arizona.edu

This work was supported by grants from A Foundation Building Strength, and National Institute of Arthritis and Musculoskeletal and Skin Disease grant R01AR053897. Bio-CAT is supported by grant 9 P41 GM103622 and 1S10OD018090-01 from the National Institute of General Medical Sciences of the National Institutes of Health. This research used resources of the Advanced Photon Source, operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.

The U.S. Department of Energy's APS is one of the world’s most productive x-ray light source facilities. Each year, the APS provides high-brightness x-ray beams to a diverse community of more than 5,000 researchers in materials science, chemistry, condensed matter physics, the life and environmental sciences, and applied research. Researchers using the APS produce over 2,000 publications each year detailing impactful discoveries, and solve more vital biological protein structures than users of any other x-ray light source research facility. APS x-rays are ideally suited for explorations of materials and biological structures; elemental distribution; chemical, magnetic, electronic states; and a wide range of technologically important engineering systems from batteries to fuel injector sprays, all of which are the foundations of our nation’s economic, technological, and physical well-being.

Argonne National Laboratory seeks solutions to pressing national problems in science and technology. The nation's first national laboratory, Argonne conducts leading-edge basic and applied scientific research in virtually every scientific discipline. Argonne researchers work closely with researchers from hundreds of companies, universities, and federal, state and municipal agencies to help them solve their specific problems, advance America's scientific leadership and prepare the nation for a better future. With employees from more than 60 nations, Argonne is managed by UChicago Argonne, LLC, for the U.S. DOE Office of Science.

The U.S. Department of Energy's Office of Science is the single largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time. For more information, visit the Office of Science website.